Advertisement

Reflections on a career in epilepsy: An unplanned journey

Published:February 24, 2016DOI:https://doi.org/10.1016/j.yebeh.2016.01.026
      The Editors have asked me to “write a synopsis of (my) career for the historical record”. The invitation made me feel honored but confused: who would be interested in my past? My route was irregular, making it unfeasible for others to follow. I do not have a doctoral degree; I am largely self-taught in the fields that developed after my university years. Thus, I am an aberration in the standard academic path toward a career in research, not a role model. My journey was not planned; I had no career goals. Things just happened, one after another. This note could have been a series of unconnected short stories, but instead, I will present a series of chapters that develop a theme.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Epilepsy & Behavior
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Cramer J.A.
        • Mattson R.H.
        Valproic acid: in vitro plasma protein binding and interaction with phenytoin.
        Ther Drug Monit. 1979; 1: 105-116
        • Cramer J.A.
        • Mattson R.H.
        Valproic acid: in vitro plasma protein binding and interaction with phenytoin.
        Ther Drug Monit. 1979; 1: 105-116
        • Cramer J.A.
        • Bennett D.B.
        • Mattson R.H.
        Ultrafiltration of valproic acid by two methods.
        Clin Chem. 1983; 29: 1441-1442
        • Mattson R.H.
        • Cramer J.A.
        • Collins J.F.
        • Smith D.B.
        • Delgado-Escueta A.V.
        • et al.
        Comparison of carbamazepine, phenobarbital, phenytoin and primidone in partial and secondarily generalized tonic–clonic seizures.
        N Engl J Med. 1985; 313: 145-151
        • Mattson R.H.
        • Cramer J.A.
        • Collins J.F.
        • Dept. of Veterans Affairs Epilepsy Cooperative Study No. 264 Group
        A comparison of valproate with carbamazepine for the treatment of partial seizures and secondarily generalized tonic–clonic seizures in adults.
        N Engl J Med. 1992; 327: 765-771
        • Mattson R.H.
        • Cramer J.A.
        • Delgado-Escueta A.V.
        • Smith D.B.
        • Collins J.F.
        • VA Epilepsy Cooperative Study Group
        A design for the prospective evaluation of the efficacy and toxicity of antiepileptic drugs in adults.
        Neurology. 1983; 33: 14-25
        • Smith D.B.
        • Delgado-Escueta A.V.
        • Cramer J.A.
        • Mattson R.H.
        Historical perspective on the choice of antiepileptic drugs for the treatment of seizures in adults.
        Neurology. 1983; 33: 2-7
        • Delgado-Escueta A.V.
        • Mattson R.H.
        • Smith D.B.
        • Cramer J.A.
        • Collins J.F.
        Principles in designing clinical trials for antiepileptic drugs.
        Neurology. 1983; 33: 8-13
        • Cramer J.A.
        • Smith D.B.
        • Mattson R.H.
        • Delgado-Escueta A.V.
        • Collins J.F.
        • VA Epilepsy Cooperative Study Group
        A method of quantification for the evaluation of antiepileptic drug therapy.
        Neurology. 1983; 33: 26-37
        • Cramer J.A.
        • Mattson R.H.
        • Prevey M.L.
        • Ouellette V.L.
        How often is medication taken as prescribed? A novel assessment technique.
        JAMA. 1989; 261: 3273-3277
      1. Cramer J.A. Spilker B. Patient compliance in medical practice and clinical trials. Raven Press, New York1991
        • Claxton A.J.
        • Cramer J.A.
        • Pierce C.
        Medication compliance: the importance of the dosing regimen.
        Clin Ther. 2001; 23: 1296-1310
        • Cramer J.A.
        • Roy A.
        • Burrell A.
        • Fairchild C.
        • Fuldeore M.
        • Ollendorf D.
        • et al.
        Medication compliance and persistence: consensus on terminology and definitions.
        Value Health. 2008; 11: 44-54
        • Devinsky O.
        • Vickrey B.G.
        • Cramer J.A.
        • Perrine K.
        • Hermann B.
        • Meador K.
        • et al.
        Development of the Quality of Life in Epilepsy Inventory.
        Epilepsia. 1995; 36: 1089-1104
        • Cramer J.A.
        • Perrine K.
        • Devinsky O.
        • Bryant-Constock L.
        • Meador K.
        • Hermann B.P.
        Development and cross-cultural translation of a 31-item quality of life inventory (QOLIE-31).
        Epilepsia. 1998; 39: 81-88
        • Cramer J.A.
        • Perrine K.
        • Devinsky O.
        • Meador K.
        A brief questionnaire to screen for quality of life in epilepsy: the QOLIE-10.
        Epilepsia. 1996; 37: 577-582
        • Cramer J.A.
        • Westbrook L.E.
        • Devinsky O.
        • Perrine K.
        • Glassman M.B.
        • Camfield C.
        Development of the Quality of Life in Epilepsy Inventory for adolescents: the QOLIE-AD-48.
        Epilepsia. 1999; 40: 1114-1121
        • Borghs S.
        • de La Loge C.
        • Cramer J.
        Defining minimally important change in QOLIE-31 scores: estimates from three placebo-controlled lacosamide trials in patients with partial onset seizures.
        Epilepsy Behav. 2012; 23: 230-234
        • Cramer J.A.
        • Baker G.A.
        • Jacoby A.
        Development of a new seizure severity questionnaire: initial reliability and validity testing.
        Epilepsy Res. 2002; 48: 187-197
        • Cramer J.A.
        • de la Loge C.
        • Brabant Y.
        • Borghs S.
        Determining minimal important change thresholds for the Seizure Severity Questionnaire (SSQ).
        Epilepsy Behav. 2014; 31: 286-290
        • Fisher R.S.
        • Nunes G.
        • Roberts S.E.
        • Cramer J.A.
        The Personal Impact of Epilepsy Scale (PIES).
        Epilepsy Behav. 2015; 42: 140-146
        • Rosenheck R.
        • Cramer J.A.
        • Xu W.
        • Thomas J.
        • Henderson W.
        • Frisman L.
        • et al.
        A comparison of clozapine and haloperidol for hospitalized patients with refractory schizophrenia.
        N Engl J Med. 1997; 337: 809-815
        • Krystal J.H.
        • Cramer J.A.
        • Krol W.F.
        • Kirk G.F.
        • Rosenheck R.
        • VA Naltrexone Cooperative Study #425 Group
        Naltrexone in the treatment of alcohol dependence.
        N Engl J Med. 2001; 345: 1734-1739
        • Krystal J.H.
        • Rosenheck R.A.
        • Cramer J.A.
        • Vessicchio J.C.
        • Jones K.M.
        • Vertrees J.E.
        • et al.
        Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military-service related PTSD — a randomized study.
        JAMA. 2011; 306: 493-502
        • Rosenheck R.
        • Cramer J.A.
        • Xu W.
        • Thomas J.
        • Henderson W.
        • Frisman L.
        • et al.
        A comparison of clozapine and haloperidol for hospitalized patients with refractory schizophrenia.
        N Engl J Med. 1997; 337: 809-815
        • Cramer J.A.
        • Wang Zhixiao J.
        • Chang E.
        • Powers A.
        • Copher R.
        • Cherepanov D.
        • et al.
        Healthcare utilization and costs in adults with stable and uncontrolled epilepsy.
        Epilepsy Behav. 2014; 31: 356-362